Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

AJVS. 2017; 54(1): 117-126


Potential Ameliorative Effects of Alpha Lipoic Acid and Silymarin on Thioacetamide-Induced Hepatic Damage in Rats

Alyaa R. Salama, Samah S. Oda, Asmaa F. Khafaga, Mohamed A. Hashem.




Abstract

The present study was designed to study the protective effects of alpha lipoic acid (ALA) and silymarin (SIL) against thioacetamide (TAA)-induced hepatic damage. Sixty male albino rats were divided into 6 groups (10 rats each); control group, TAA-treated group: injected intraperitoneally with TAA 250 mg/kg bwt/day three times a week, ALA-treated group: received ALA 100 mg/kg bwt/day) orally three times a week, SIL-treated group: received SIL 100 mg/kg bwt/day orally three times a week, TAA+ALA-treated group, and TAA+SIL-treated group at the same previous doses and routes for ten weeks.
Results showed that TAA induced a significant increase in serum liver enzymes, total and direct bilirubin, total cholesterol and triglycerides levels after four and ten weeks of the treatments. While the serum levels of total proteins, albumin and high density lipoprotein-cholesterol revealed a significant decrease. TAA injection resulted in an increase in the hepatic lipid peroxidation and decreased antioxidant biomarker levels. Histopathologically, TAA revealed marked degenerative, necrotic and fibrotic alterations in the liver, particularly during ten weeks post-treatment. ALA and SIL- treatment ameliorated TAA-induced oxidative damage, alterations in the liver function tests and liver histopathology. However, ALA demonstrated better hepatic protection against TAA-induced liver damage as compared to SIL. The study clearly concluded that ALA has more powerful antioxidant properties than SIL.

Key words: liver, thioacetamide, silymarin, alpha lipoic acid, rats.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.